Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Iovance Biotherapeutics Inc

IOVA
Current price
9.76 USD +0.09 USD (+0.93%)
Last closed 9.76 USD
ISIN US4622601007
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 916 769 280 USD
Yield for 12 month +138.63 %
1Y
3Y
5Y
10Y
15Y
IOVA
21.11.2021 - 28.11.2021

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Address: 825 Industrial Road, San Carlos, CA, United States, 94070

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24.42 USD

P/E ratio

Dividend Yield

Current Year

+1 189 000 USD

Last Year

+238 000 USD

Current Quarter

+31 106 000 USD

Last Quarter

+715 000 USD

Current Year

-31 938 000 USD

Last Year

-21 135 000 USD

Current Quarter

-5 640 000 USD

Last Quarter

-11 820 000 USD

Key Figures IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -439 252 992 USD
Operating Margin TTM -327.64 %
PE Ratio
Return On Assets TTM -33.35 %
PEG Ratio
Return On Equity TTM -65.36 %
Wall Street Target Price 24.42 USD
Revenue TTM 32 772 000 USD
Book Value 2.59 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 12969.7 %
Dividend Yield
Gross Profit TTM
Earnings per share -1.67 USD
Diluted Eps TTM -1.67 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IOVA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:100
Payout Ratio
Last Split Date 26.09.2013
Dividend Date

Stock Valuation IOVA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 78.9061
Price Sales TTM 89.0019
Enterprise Value EBITDA -8.6776
Price Book MRQ 3.7952

Financials IOVA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IOVA

For 52 weeks

3.21 USD 18.33 USD
50 Day MA 9.83 USD
Shares Short Prior Month 57 686 674
200 Day MA 10.42 USD
Short Ratio 9.56
Shares Short 60 293 439
Short Percent 21.97 %